Title
Comparative study of fecal calprotectin levels in ulcerative colitis versus irritable bowel syndrome
Authors
Geethika Sai Satyavasukiaparna Garaga1,*, Kalvakota Maninithya2, Nadampalli Deepica Rani3 & Aksah Dayan2
Affiliation
1Department of Gastroenterology and Hepatology, Yashoda Hospitals, Hyderabad, Telangana, India; 2Department of Medical Gastroenterology, Yashoda hospital, Hyderabad, Telangana, India; 3Department of General Medicine, Yashoda hospitals, Hyderabad, Telangana, India; *Corresponding author
Geethika Sai Satyavasukiaparna Garaga - E-mail: dr.geethikasuresh@gmail.com
Kalvakota Maninithya - E-mail: kalvakota.maninithya.2021@gmail.com
Nadampalli Deepica Rani - E-mail: deepica.nadampalli18@gmail.com
Aksah Dayan - E-mail: aksahdayan14@gmail.com
Article Type
Research Article
Date
Received July 1, 2025; Revised July 31, 2025; Accepted July 31, 2025, Published July 31, 2025
Abstract
Fecal calprotectin has been evaluated on its ability to differentiate between ulcerative colitis (UC) and irritable bowel syndrome (IBS). Hence, sixty patients were stratified according to clinical and histological characteristic as UC (Group A) and IBS (Group B). The levels of calprotectin in UC patients (623.5 0 g) were significantly higher than in IBS patients (36.4 0 g), (p < 0.001). The high presence was observed in 93.3 percent of UC subjects and only 6.7 percent of IBS subjects. Thus, fecal calprotectin works well in distinguishing UC and IBS, and facilitates the non-invasive diagnosis of UC.
Keywords
Fecal calprotectin, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, non-invasive biomarker, ELISA
Citation
Garaga et al. Bioinformation 21(7): 1850-1853 (2025)
Edited by
Hiroj Bagde MDS, (PhD), PGDCR, PGDHHM, PGDL, PGDM
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
